Five-year View
Over the next 5 years, the quadrivalent inactivated influenza vaccine will become more widely used. Advances in the search for a universal vaccine, targeting a common antigen that is not subject to genetic modifications, may modify our approach to vaccination against influenza. In the meantime, improved influenza surveillance systems and models for predicting which influenza strains are most likely to circulate need to be developed.
Acknowledgments
The author would like to thank Sandrine Samson (Sanofi Pasteur MSD) for her critical review and useful suggestions. As well as Sanofi Pasteur MSD for providing funding to write this manuscript and Margaret Haugh (MediCom Consult) for translation and editing services.
Financial & competing interests disclosure
Funding was provided by Sanofi Pasteur MSD. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Margaret Haugh (MediCom Consult) provided translation and editing services, which was funded by Sanofi Pasteur MSD.
Expert Rev Vaccines. 2013;12(9):1085-1094. © 2013 Expert Reviews Ltd.